Enorama Pharma H1 FY26 operating loss narrows to SEK 22.58 million; net sales swing to SEK -109,000

• Enorama Pharma posted no net sales for April–June, down from SEK 733,000 a year earlier.
• Operating loss narrowed to SEK 11.71 million from SEK 15.32 million in the prior-year quarter.
• Loss before tax improved to SEK 13.12 million from SEK 18.71 million a year earlier; EPS was SEK -0.18.
• For January–June, net sales turned negative to SEK -109,000 from SEK 1.18 million a year earlier.
• Operating loss narrowed to SEK 22.58 million from SEK 32 million; FDA upheld a Refuse-to-File decision on PMTA filings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enorama Pharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202608190230BITN____UKPR__SV_20260818-BIT-9213-0) on August 19, 2026, and is solely responsible for the information contained therein.